Policy & Regulation
AbCellera Launches Second Phase of Global Headquarters Expansion
23 September 2022 - - Canada-based antibody discovery technology company AbCellera (NASDAQ: ABCL) has launched the second phase of its global headquarters expansion by breaking ground on its new facility in Vancouver, Canada, the company said.

The 380,000-square-foot tech campus will include lab and office spaces to support AbCellera's capabilities in bringing new antibody-based medicines from target to the clinic.

The expansion will accommodate the growth of AbCellera's existing 450+ person team and the investments into forward integration of translational science, process development, and clinical manufacturing capabilities.

AbCellera empowers its emerging biopharma partners to advance discovery programs without having to build the underlying capabilities, teams, and infrastructure.

For its large biopharma partners, AbCellera's integrated technologies allow intractable programs to be unlocked seamlessly within a single platform.

AbCellera broke ground on the first phase of its global headquarters in the heart of Vancouver -- a 170,000-square-foot facility at 150 West 4th Avenue being developed in 50/50 partnership with Dayhu -- in April 2021, with occupancy expected in late 2023.

The second facility, which is directly adjacent to the first, is a 210,000-square-foot building at 110 West 4th Avenue. AbCellera is developing it in a 50/50 partnership with Beedie, with completion scheduled for 2025.

The two facilities are located a short distance away from the site of AbCellera's planned 130,000-square-foot clinical manufacturing facility, which was announced in June 2021.

AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease.

AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development.